Oklahoma 2024 Regular Session

Oklahoma House Bill HB1987 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1		-	An Act
2		-	ENROLLED HOUSE
	1	+
	2	+
	3	+	SENATE FLOOR VERSION - HB1987 SFLR Page 1
	4	+	(Bold face denotes Committee Amendments) 1
	5	+	2
	6	+	3
	7	+	4
	8	+	5
	9	+	6
	10	+	7
	11	+	8
	12	+	9
	13	+	10
	14	+	11
	15	+	12
	16	+	13
	17	+	14
	18	+	15
	19	+	16
	20	+	17
	21	+	18
	22	+	19
	23	+	20
	24	+	21
	25	+	22
	26	+	23
	27	+	24
	28	+
	29	+	SENATE FLOOR VERSION
	30	+	April 13, 2023
	31	+
	32	+
	33	+	ENGROSSED HOUSE
3	34		BILL NO. 1987 By: Dollens, Pae, Luttrell,
4	35		Echols, Waldron, Hefner and
5	36		Deck of the House
6	37
7	38		and
8	39
9	40		Rader of the Senate
10		-
11		-
12	41
13	42
14	43
15	44
16	45		An Act relating to public health and safety; amending
17	46		63 O.S. 2021, Section 2-101, as amended by Section 4,
18	47		Chapter 265, O.S.L. 2022 (63 O.S. Supp. 2022, Section
19	48		2-101), which relates to the Uniform Controlled
20	49		Dangerous Substances Act; adding exception to certain
21	50		defined term; and providing an effective date.
22	51
23	52
24	53
25		-	SUBJECT: Public health and safety- Uniformed Controlled
26		-	Dangerous Substance Act
27	54
28	55		BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
29		-
30	56		SECTION 1. AMENDATORY 63 O.S. 2021, Section 2-101, as
31	57		amended by Section 4, Chapter 265, O.S.L. 2022 (63 O. S. Supp. 2022,
32	58		Section 2-101), is amended to read as follows:
33		-
34	59		Section 2-101. As used in the Uniform Controlled Dangerous
35	60		Substances Act:
36		-
37	61		1. "Administer" means the direct application of a controlled
38	62		dangerous substance, whether by injection, inhalation, ingestion or
39	63		any other means, to the body of a patient, animal or research
40	64		subject by:
41	65
	66	+	SENATE FLOOR VERSION - HB1987 SFLR Page 2
	67	+	(Bold face denotes Committee Amendments) 1
	68	+	2
	69	+	3
	70	+	4
	71	+	5
	72	+	6
	73	+	7
	74	+	8
	75	+	9
	76	+	10
	77	+	11
	78	+	12
	79	+	13
	80	+	14
	81	+	15
	82	+	16
	83	+	17
	84	+	18
	85	+	19
	86	+	20
	87	+	21
	88	+	22
	89	+	23
	90	+	24
	91	+
42	92		a. a practitioner (or, in the presence of the
43	93		practitioner, by the authorized agent of the
44	94		practitioner), or
45	95		b. the patient or research subject at the direction and
46		-	in the presence of the practitioner; ENR. H. B. NO. 1987 Page 2
47		-
	96	+	in the presence of the practitioner;
48	97		2. "Agent" means a peace officer appointed by and who acts on
49	98		behalf of the Director of the Oklahoma State Bureau of Narcotics and
50	99		Dangerous Drugs Control or an authorized person who acts on behalf
51	100		of or at the direction of a person who manufactures, distrib utes,
52	101		dispenses, prescribes, administers or uses for scientific purposes
53	102		controlled dangerous substances but does not include a common or
54	103		contract carrier, public warehouser or employee thereof, or a person
55	104		required to register under the Uniform Controlled Dangerous
56	105		Substances Act;
57		-
58	106		3. "Board" means the Advisory Board to the Director of the
59	107		Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
60		-
61	108		4. "Bureau" means the Oklahoma State Bureau of Narcotics and
62	109		Dangerous Drugs Control;
63		-
64	110		5. "Coca leaves" includes cocaine and any compound,
65	111		manufacture, salt, derivative, mixture or preparation of coca
66	112		leaves, except derivatives of coca leaves which do not contain
67	113		cocaine or ecgonine;
68		-
69	114		6. "Commissioner" or "Director" means the Director of the
70	115		Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
	116	+
	117	+	SENATE FLOOR VERSION - HB1987 SFLR Page 3
	118	+	(Bold face denotes Committee Amendments) 1
	119	+	2
	120	+	3
	121	+	4
	122	+	5
	123	+	6
	124	+	7
	125	+	8
	126	+	9
	127	+	10
	128	+	11
	129	+	12
	130	+	13
	131	+	14
	132	+	15
	133	+	16
	134	+	17
	135	+	18
	136	+	19
	137	+	20
	138	+	21
	139	+	22
	140	+	23
	141	+	24
71	142
72	143		7. "Control" means to add, remove or change the placement of a
73	144		drug, substance or immediate precursor under the Uniform Controlled
74	145		Dangerous Substances Act;
75		-
76	146		8. "Controlled dangerous substance" means a drug, substance or
77	147		immediate precursor in Schedules I through V of the Uniform
78	148		Controlled Dangerous Substances Act or any drug, substance or
79	149		immediate precursor listed either temporarily or permanently as a
80	150		federally controlled substance. Any conflict between state and
81	151		federal law with regard to the particular schedule in which a
82	152		substance is listed shall be resolved in favor of state law;
83		-
84	153		9. "Counterfeit substance" means a controlled substance which,
85	154		or the container or labeling of which without authorization , bears
86	155		the trademark, trade name or other identifying marks, imprint,
87	156		number or device or any likeness thereof of a manufacturer,
88	157		distributor or dispenser other than the person who in fact
89	158		manufactured, distributed or dispensed the substance;
90	159		10. "Deliver" or "delivery" means the actual, constructive or
91		-	attempted transfer from one person to another of a controlled ~~ENR. H. B. NO. 1987 Page 3~~
	160	+	attempted transfer from one person to another of a controlled
92	161		dangerous substance or drug paraphernalia, whether or not there is
93	162		an agency relationship;
94		-
95	163		11. "Dispense" means to deliver a controlled danger ous
96	164		substance to an ultimate user or human research subject by or
97	165		pursuant to the lawful order of a practitioner, including the
98	166		prescribing, administering, packaging, labeling or compounding
	167	+
	168	+	SENATE FLOOR VERSION - HB1987 SFLR Page 4
	169	+	(Bold face denotes Committee Amendments) 1
	170	+	2
	171	+	3
	172	+	4
	173	+	5
	174	+	6
	175	+	7
	176	+	8
	177	+	9
	178	+	10
	179	+	11
	180	+	12
	181	+	13
	182	+	14
	183	+	15
	184	+	16
	185	+	17
	186	+	18
	187	+	19
	188	+	20
	189	+	21
	190	+	22
	191	+	23
	192	+	24
	193	+
99	194		necessary to prepare the substance for such distribution.
100	195		"Dispenser" is a practitioner who delivers a controlled dangerous
101	196		substance to an ultimate user or human research subject;
102		-
103	197		12. "Distribute" means to deliver other than by administering
104	198		or dispensing a controlled dangerous substance;
105		-
106	199		13. "Distributor" means a commercial entity engaged in the
107	200		distribution or reverse distribution of narcotics and dangerous
108	201		drugs and who complies with all regulations promulgated by the
109	202		federal Drug Enforcement Administration and the Oklahoma State
110	203		Bureau of Narcotics and Dangerous Drugs Control;
111		-
112	204		14. "Drug" means articles:
113		-
114	205		a. recognized in the official United States Pharmacopeia,
115	206		official Homeopathic Pharmacopoeia of the United
116	207		States, or official National Formulary, or any
117	208		supplement to any of them,
118		-
119	209		b. intended for use in the diagn osis, cure, mitigation,
120	210		treatment or prevention of disease in man or other
121	211		animals,
122		-
123	212		c. other than food, intended to affect the structure or
124	213		any function of the body of man or other animals, and
125		-
126	214		d. intended for use as a component of any article
127	215		specified in this paragraph;
128		-
129	216		provided, however, the term "drug" does not include devices or their
130	217		components, parts or accessories;
	218	+
	219	+	SENATE FLOOR VERSION - HB1987 SFLR Page 5
	220	+	(Bold face denotes Committee Amendments) 1
	221	+	2
	222	+	3
	223	+	4
	224	+	5
	225	+	6
	226	+	7
	227	+	8
	228	+	9
	229	+	10
	230	+	11
	231	+	12
	232	+	13
	233	+	14
	234	+	15
	235	+	16
	236	+	17
	237	+	18
	238	+	19
	239	+	20
	240	+	21
	241	+	22
	242	+	23
	243	+	24
131	244
132	245		15. "Drug-dependent person" means a person who is using a
133	246		controlled dangerous substance and who is in a state of psychic or
134	247		physical dependence, or both, arising from administration of that
135	248		controlled dangerous substance on a continuous basis. Drug
136		-	dependence is characterized by behavioral and other responses which ~~ENR. H. B. NO. 1987 Page 4~~
	249	+	dependence is characterized by behavioral and other responses which
137	250		include a strong compulsion to take the substance on a continuous
138	251		basis in order to experience its psychic effects, or to avoid the
139	252		discomfort of its absence;
140		-
141	253		16. "Home care agency" means any sole proprietorship,
142	254		partnership, association, corporation, or other organization which
143	255		administers, offers, or provides home care serv ices, for a fee or
144	256		pursuant to a contract for such services, to clients in their place
145	257		of residence;
146		-
147	258		17. "Home care services" means skilled or personal care
148	259		services provided to clients in their place of residence for a fee;
149		-
150	260		18. "Hospice" means a centrally administered, nonprofit or for-
151	261		profit, medically directed, nurse-coordinated program which provides
152	262		a continuum of home and inpatient care for the terminally ill
153	263		patient and the patient's family. Such term shall also include a
154	264		centrally administered, n onprofit or for-profit, medically directed,
155	265		nurse-coordinated program if such program is licensed pursuant to
156	266		the provisions of the Uniform Controlled Dangerous Substances Act.
157	267		A hospice program offers palliative and supportive care to meet the
158	268		special needs arising out of the physical, emotional and spiritual
	269	+
	270	+	SENATE FLOOR VERSION - HB1987 SFLR Page 6
	271	+	(Bold face denotes Committee Amendments) 1
	272	+	2
	273	+	3
	274	+	4
	275	+	5
	276	+	6
	277	+	7
	278	+	8
	279	+	9
	280	+	10
	281	+	11
	282	+	12
	283	+	13
	284	+	14
	285	+	15
	286	+	16
	287	+	17
	288	+	18
	289	+	19
	290	+	20
	291	+	21
	292	+	22
	293	+	23
	294	+	24
	295	+
159	296		stresses which are experienced during the final stages of illness
160	297		and during dying and bereavement. This care is available twenty-
161	298		four (24) hours a day, seven (7) days a week, and is provided on the
162	299		basis of need, regardless of ability to pay. "Class A" Hospice
163	300		refers to Medicare-certified hospices. "Class B" refers to all
164	301		other providers of hospice services;
165		-
166	302		19. "Imitation controlled substance" means a substance that is
167	303		not a controlled dangerous substance, which by dosage unit
168	304		appearance, color, shape, size, markings or by representations made,
169	305		would lead a reasonable person to believe that the substance is a
170	306		controlled dangerous substance. In the event the appearance of the
171	307		dosage unit is not r easonably sufficient to establish that the
172	308		substance is an "imitation controlled substance", the court or
173	309		authority concerned should consider, in addition to all other
174	310		factors, the following factors as related to "representations made"
175	311		in determining wheth er the substance is an "imitation controlled
176	312		substance":
177		-
178	313		a. statements made by an owner or by any other person in
179	314		control of the substance concerning the nature of the
180	315		substance, or its use or effect,
181		-	ENR. H. B. NO. 1987 Page 5
182	316		b. statements made to the recipient that the substance
183	317		may be resold for inordinate profit,
184		-
185	318		c. whether the substance is packaged in a manner normally
186	319		used for illicit controlled substances,
	320	+
	321	+	SENATE FLOOR VERSION - HB1987 SFLR Page 7
	322	+	(Bold face denotes Committee Amendments) 1
	323	+	2
	324	+	3
	325	+	4
	326	+	5
	327	+	6
	328	+	7
	329	+	8
	330	+	9
	331	+	10
	332	+	11
	333	+	12
	334	+	13
	335	+	14
	336	+	15
	337	+	16
	338	+	17
	339	+	18
	340	+	19
	341	+	20
	342	+	21
	343	+	22
	344	+	23
	345	+	24
187	346
188	347		d. evasive tactics or actions utilized by the owner or
189	348		person in control of the substance to avoid detection
190	349		by law enforcement authorities,
191		-
192	350		e. prior convictions, if any, of an owner, or any other
193	351		person in control of the object, under state or
194	352		federal law related to controlled substances or fraud,
195	353		and
196		-
197	354		f. the proximity of the substances to controlled
198	355		dangerous substances;
199		-
200	356		20. "Immediate precursor" means a substance which the Director
201	357		has found to be and by regulation designates as being the principal
202	358		compound commonly used or produced primarily for use, and which is
203	359		an immediate chemical intermediary used, or likely to be us ed, in
204	360		the manufacture of a controlled dangerous substance, the control of
205	361		which is necessary to prevent, curtail or limit such manufacture;
206		-
207	362		21. "Laboratory" means a laboratory approved by the Director as
208	363		proper to be entrusted with the custody of control led dangerous
209	364		substances and the use of controlled dangerous substances for
210	365		scientific and medical purposes and for purposes of instruction;
211		-
212	366		22. "Manufacture" means the production, preparation,
213	367		propagation, compounding or processing of a controlled danger ous
214	368		substance, either directly or indirectly by extraction from
215	369		substances of natural or synthetic origin, or independently by means
216	370		of chemical synthesis or by a combination of extraction and chemical
	371	+
	372	+	SENATE FLOOR VERSION - HB1987 SFLR Page 8
	373	+	(Bold face denotes Committee Amendments) 1
	374	+	2
	375	+	3
	376	+	4
	377	+	5
	378	+	6
	379	+	7
	380	+	8
	381	+	9
	382	+	10
	383	+	11
	384	+	12
	385	+	13
	386	+	14
	387	+	15
	388	+	16
	389	+	17
	390	+	18
	391	+	19
	392	+	20
	393	+	21
	394	+	22
	395	+	23
	396	+	24
	397	+
217	398		synthesis. "Manufacturer" includes any person who pac kages,
218	399		repackages or labels any container of any controlled dangerous
219	400		substance, except practitioners who dispense or compound
220	401		prescription orders for delivery to the ultimate consumer;
221		-
222	402		23. "Marijuana" means all parts of the plant Cannabis sativa
223	403		L., whether growing or not; the seeds thereof; the resin extracted
224	404		from any part of such plant; and every compound, manufacture, salt,
225	405		derivative, mixture or preparation of such plant, its seeds or
226		-	resin, but shall not include: ENR. H. B. NO. 1987 Page 6
227		-
	406	+	resin, but shall not include:
228	407		a. the mature stalks of such plant o r fiber produced from
229	408		such stalks,
230		-
231	409		b. oil or cake made from the seeds of such plant,
232	410		including cannabidiol derived from the seeds of the
233	411		marijuana plant,
234		-
235	412		c. any other compound, manufacture, salt, derivative,
236	413		mixture or preparation of such mature stalks (ex cept
237	414		the resin extracted therefrom), including cannabidiol
238	415		derived from mature stalks, fiber, oil or cake,
239		-
240	416		d. the sterilized seed of such plant which is incapable
241	417		of germination,
242		-
243	418		e. for any person participating in a clinical trial to
244	419		administer cannabidiol for the treatment of severe
245	420		forms of epilepsy pursuant to Section 2-802 of this
246	421		title, a drug or substance approved by the federal
	422	+
	423	+	SENATE FLOOR VERSION - HB1987 SFLR Page 9
	424	+	(Bold face denotes Committee Amendments) 1
	425	+	2
	426	+	3
	427	+	4
	428	+	5
	429	+	6
	430	+	7
	431	+	8
	432	+	9
	433	+	10
	434	+	11
	435	+	12
	436	+	13
	437	+	14
	438	+	15
	439	+	16
	440	+	17
	441	+	18
	442	+	19
	443	+	20
	444	+	21
	445	+	22
	446	+	23
	447	+	24
	448	+
247	449		Food and Drug Administration for use by those
248	450		participants,
249		-
250	451		f. for any person or the parents, legal guardians or
251	452		caretakers of the person who have received a written
252	453		certification from a physician licensed in this state
253	454		that the person has been diagnosed by a physician as
254	455		having Lennox-Gastaut syndrome, Dravet syndrome, also
255	456		known as severe myoclonic epilepsy of infancy, or any
256	457		other severe form of epilepsy that is not adequately
257	458		treated by traditional medical therapies, spasticity
258	459		due to multiple sclerosis or due to paraplegia,
259	460		intractable nausea and vomiting, appetite stimulation
260	461		with chronic wasting diseases, the substance
261	462		cannabidiol, a nonpsychoactive cannabinoid, found in
262	463		the plant Cannabis sativa L. or any other preparation
263	464		thereof, that has a tetrahydrocannabinol concentration
264	465		of not more than three-tenths of one percent (0.3%)
265	466		and that is delivered to the patient in the form of a
266	467		liquid,
267	468		g. any federal Food-and-Drug-Administration-approved drug
268	469		or substance, or
	470	+	h. industrial hemp, from the plant Cannabis sativa L. and
	471	+	any part of such plant, whether growing or not, with a
	472	+	delta-9 tetrahydrocannabinol concentration of not more
269	473
270		-	h. industrial hemp, from the plant Cannabis sativa L. and
271		-	any part of such plant, whether growing or not, with a ENR. H. B. NO. 1987 Page 7
272		-	delta-9 tetrahydrocannabinol concentration of not more
	474	+	SENATE FLOOR VERSION - HB1987 SFLR Page 10
	475	+	(Bold face denotes Committee Amendments) 1
	476	+	2
	477	+	3
	478	+	4
	479	+	5
	480	+	6
	481	+	7
	482	+	8
	483	+	9
	484	+	10
	485	+	11
	486	+	12
	487	+	13
	488	+	14
	489	+	15
	490	+	16
	491	+	17
	492	+	18
	493	+	19
	494	+	20
	495	+	21
	496	+	22
	497	+	23
	498	+	24
	499	+
273	500		than three-tenths of one percent (0.3%) on a dry-
274	501		weight basis which shall only be grown pursuant to the
275	502		Oklahoma Industrial Hemp Program and may be shipped
276	503		intrastate and interstate;
277		-
278	504		24. "Medical purpose" means an intention to utilize a
279	505		controlled dangerous substance for physical or mental treatment, for
280	506		diagnosis, or for the prevention of a disease condition not in
281	507		violation of any state or federal law and not for the purpose of
282	508		satisfying physiological or psychological dependence or other abuse;
283		-
284	509		25. "Mid-level practitioner" means an Advanced Practice
285	510		Registered Nurse as defined and within parameters specified in
286	511		Section 567.3a of Title 59 of the Oklahoma Statutes, or a certified
287	512		animal euthanasia technician as defined in Section 698.2 of Title 59
288	513		of the Oklahoma Statutes, or an animal control officer registered by
289	514		the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control
290	515		under subsection B of Section 2-301 of this title within the
291	516		parameters of such officer's duties under Sections 501 throug h 508
292	517		of Title 4 of the Oklahoma Statutes;
293		-
294	518		26. "Narcotic drug" means any of the following, whether
295	519		produced directly or indirectly by extraction from substances of
296	520		vegetable origin, or independently b y means of chemical synthesis,
297	521		or by a combination of e xtraction and chemical synthesis:
	522	+	a. opium, coca leaves and opiates,
298	523
299		-	a. opium, coca leaves and opiates,
	524	+	SENATE FLOOR VERSION - HB1987 SFLR Page 11
	525	+	(Bold face denotes Committee Amendments) 1
	526	+	2
	527	+	3
	528	+	4
	529	+	5
	530	+	6
	531	+	7
	532	+	8
	533	+	9
	534	+	10
	535	+	11
	536	+	12
	537	+	13
	538	+	14
	539	+	15
	540	+	16
	541	+	17
	542	+	18
	543	+	19
	544	+	20
	545	+	21
	546	+	22
	547	+	23
	548	+	24
300	549
301	550		b. a compound, manufacture, salt, derivative or
302	551		preparation of opium, coca leaves or opiates,
303		-
304	552		c. cocaine, its salts, optical and geo metric isomers, and
305	553		salts of isomers,
306		-
307	554		d. ecgonine, its derivatives, their salts, isomers and
308	555		salts of isomers, and
309		-
310	556		e. a substance, and any compound, manufacture, salt,
311	557		derivative or preparation thereof, which is chemically
312	558		identical with any of the substan ces referred to in
313	559		subparagraphs a through d of this pa ragraph, except
314	560		that the words "narcotic drug" as used in Section 2-
315		-	101 et seq. of this title shall not include ~~ENR. H. B. NO. 1987 Page 8~~
	561	+	101 et seq. of this title shall not include
316	562		decocainized coca leaves or extracts of coca leaves,
317	563		which extracts do not contain cocain e or ecgonine;
318		-
319	564		27. "Opiate" or "opioid" means any Schedule II, III, IV or V
320	565		substance having an addiction-forming or addiction-sustaining
321	566		liability similar to morphine or being capable of conversion into a
322	567		drug having such addiction-forming or addiction -sustaining
323	568		liability. The terms do not include, unless specifically designated
324	569		as controlled under the Uniform Controlled Dangerous Substances Act,
325	570		the dextrorotatory isomer of 3-methoxy-n-methyl-morphinan and its
326	571		salts (dextromethorphan). The terms do include the racemic and
327	572		levorotatory forms;
328	573
	574	+	SENATE FLOOR VERSION - HB1987 SFLR Page 12
	575	+	(Bold face denotes Committee Amendments) 1
	576	+	2
	577	+	3
	578	+	4
	579	+	5
	580	+	6
	581	+	7
	582	+	8
	583	+	9
	584	+	10
	585	+	11
	586	+	12
	587	+	13
	588	+	14
	589	+	15
	590	+	16
	591	+	17
	592	+	18
	593	+	19
	594	+	20
	595	+	21
	596	+	22
	597	+	23
	598	+	24
	599	+
329	600		28. "Opium poppy" means the plant of the species Papaver
330	601		somniferum L., except the seeds thereof;
331		-
332	602		29. "Peace officer" means a police officer, sheriff, deputy
333	603		sheriff, district attorney's investigator, investigato r from the
334	604		Office of the Attorney General, or any other person elected or
335	605		appointed by law to enforce any of the criminal laws of this state
336	606		or of the United States;
337		-
338	607		30. "Person" means an individual, corporation, government or
339	608		governmental subdivision or agency, business trust, estate, trust,
340	609		partnership or association, or any other legal entity;
341		-
342	610		31. "Poppy straw" means all parts, except the seeds, of the
343	611		opium poppy, after mowing;
344		-
345	612		32. "Practitioner" means:
346		-
347	613		a. (1) a medical doctor or osteopathic physicia n,
348		-
349	614		(2) a dentist,
350		-
351	615		(3) a podiatrist,
352		-
353	616		(4) an optometrist,
354		-
355	617		(5) a veterinarian,
356		-
357	618		(6) a physician assistant or Advanced Practice
358	619		Registered Nurse under the supervision of a
359	620		licensed medical doctor or osteopathic physician,
360		-	ENR. H. B. NO. 1987 Page 9
361	621		(7) a scientific investigator, or
	622	+	(8) any other person,
362	623
363		-	(8) any other person,
	624	+	SENATE FLOOR VERSION - HB1987 SFLR Page 13
	625	+	(Bold face denotes Committee Amendments) 1
	626	+	2
	627	+	3
	628	+	4
	629	+	5
	630	+	6
	631	+	7
	632	+	8
	633	+	9
	634	+	10
	635	+	11
	636	+	12
	637	+	13
	638	+	14
	639	+	15
	640	+	16
	641	+	17
	642	+	18
	643	+	19
	644	+	20
	645	+	21
	646	+	22
	647	+	23
	648	+	24
364	649
365	650		licensed, registered or otherwise permitted to
366	651		prescribe, distribute, dispense, conduct research with
367	652		respect to, use for scientific purposes or administer
368	653		a controlled dangerous substance in the course of
369	654		professional practice or research in this state, or
370		-
371	655		b. a pharmacy, hospital, laboratory or other institution
372	656		licensed, registered or otherwise permitted to
373	657		distribute, dispense, conduct research with respect
374	658		to, use for scientific purposes or administer a
375	659		controlled dangerous substance in the course of
376	660		professional practice or research in this state;
377		-
378	661		33. "Production" includes the manufacture, planting,
379	662		cultivation, growing or harvesting of a controlled dangerous
380	663		substance;
381		-
382	664		34. "State" means the State of Oklahoma or any other state of
383	665		the United States;
384		-
385	666		35. "Ultimate user" means a person who lawfully possesses a
386	667		controlled dangerous substance for the person's own use or for the
387	668		use of a member of the person's household or for administration to
388	669		an animal owned by the person or by a member of the person's
389	670		household;
390		-
391	671		36. "Drug paraphernalia" means all equipment, products and
392	672		materials of any kind which are used, intended for use, or fashioned
393	673		specifically for use in planting, propagating, cultivating, growing,
	674	+
	675	+	SENATE FLOOR VERSION - HB1987 SFLR Page 14
	676	+	(Bold face denotes Committee Amendments) 1
	677	+	2
	678	+	3
	679	+	4
	680	+	5
	681	+	6
	682	+	7
	683	+	8
	684	+	9
	685	+	10
	686	+	11
	687	+	12
	688	+	13
	689	+	14
	690	+	15
	691	+	16
	692	+	17
	693	+	18
	694	+	19
	695	+	20
	696	+	21
	697	+	22
	698	+	23
	699	+	24
	700	+
394	701		harvesting, manufacturing, comp ounding, converting, producing,
395	702		processing, preparing, testing, analyzing, packaging, repackaging,
396	703		storing, containing, concealing, injecting, ingesting, inhaling or
397	704		otherwise introducing into the human body, a controlled dangerous
398	705		substance in violation o f the Uniform Controlled Dangerous
399	706		Substances Act including, but not limited to:
400	707		a. kits used, intended for use, or fashioned specifically
401	708		for use in planting, propagating, cultivating, growing
402	709		or harvesting of any species of plant which is a
403	710		controlled dangerous substance or from which a
404	711		controlled dangerous substance can be derived,
405		-	ENR. H. B. NO. 1987 Page 10
406	712		b. kits used, intended for use, or fashioned specifically
407	713		for use in manufacturing, compounding, converting,
408	714		producing, processing or preparing controlled
409	715		dangerous substances ,
410		-
411	716		c. isomerization devices used, intended for use, or
412	717		fashioned specifically for use in increasing the
413	718		potency of any species of plant which is a controlled
414	719		dangerous substance,
415		-
416	720		d. testing equipment used, intended for use, or fashioned
417	721		specifically for use in identifying, or in analyzing
418	722		the strength, effectiveness or purity of controlled
419	723		dangerous substances,
420	724
	725	+	SENATE FLOOR VERSION - HB1987 SFLR Page 15
	726	+	(Bold face denotes Committee Amendments) 1
	727	+	2
	728	+	3
	729	+	4
	730	+	5
	731	+	6
	732	+	7
	733	+	8
	734	+	9
	735	+	10
	736	+	11
	737	+	12
	738	+	13
	739	+	14
	740	+	15
	741	+	16
	742	+	17
	743	+	18
	744	+	19
	745	+	20
	746	+	21
	747	+	22
	748	+	23
	749	+	24
	750	+
421	751		e. scales and balances used, intended for use, or
422	752		fashioned specifically for use in weighing or
423	753		measuring controlled dangerous substances,
424		-
425	754		f. diluents and adulterants, such as quinine
426	755		hydrochloride, mannitol, mannite, dextrose and
427	756		lactose, used, intended for use, or fashioned
428	757		specifically for use in cutting controlled dangerous
429	758		substances,
430		-
431	759		g. separation gins and sifters used, intended for use, or
432	760		fashioned specifically for use in removing twigs and
433	761		seeds from, or in otherwise cleaning or refining,
434	762		marijuana,
435		-
436	763		h. blenders, bowls, containers, spoons and mixing devices
437	764		used, intended for use, or fashioned specifically for
438	765		use in compounding controlled dange rous substances,
439		-
440	766		i. capsules, balloons, envelopes and o ther containers
441	767		used, intended for use, or fashioned specifically for
442	768		use in packaging small quantities of controlled
443	769		dangerous substances,
444		-
445	770		j. containers and other objects used, intended for use,
446	771		or fashioned specifically for use in parenterally
447	772		injecting controlled dangerous substances into the
448	773		human body,
449		-	ENR. H. B. NO. 1987 Page 11
	774	+
	775	+	SENATE FLOOR VERSION - HB1987 SFLR Page 16
	776	+	(Bold face denotes Committee Amendments) 1
	777	+	2
	778	+	3
	779	+	4
	780	+	5
	781	+	6
	782	+	7
	783	+	8
	784	+	9
	785	+	10
	786	+	11
	787	+	12
	788	+	13
	789	+	14
	790	+	15
	791	+	16
	792	+	17
	793	+	18
	794	+	19
	795	+	20
	796	+	21
	797	+	22
	798	+	23
	799	+	24
	800	+
450	801		k. hypodermic syringes, needles and other objects used,
451	802		intended for use, or fashioned specifically for use in
452	803		parenterally injecting controlled dan gerous substances
453	804		into the human body,
454		-
455	805		l. objects used, intended for use, or fashioned
456	806		specifically for use in ingesting, inhaling or
457	807		otherwise introducing marijuana, cocaine, hashish or
458	808		hashish oil into the human body, such as:
459		-
460	809		(1) metal, wooden, acrylic, glass, stone, plastic or
461	810		ceramic pipes with or without screens, permanent
462	811		screens, hashish heads or punctured metal bowls,
463		-
464	812		(2) water pipes,
465		-
466	813		(3) carburetion tubes and devices,
467		-
468	814		(4) smoking and carburetion masks,
469		-
470	815		(5) roach clips, meaning objects used to hold burning
471	816		material, such as a marijuana cigarette, that has
472	817		become too small or too short to be held in the
473	818		hand,
474		-
475	819		(6) miniature cocaine spoons and cocaine vials,
476		-
477	820		(7) chamber pipes,
478		-
479	821		(8) carburetor pipes,
480		-
481	822		(9) electric pipes,
482		-
483	823		(10) air-driven pipes,
484		-
485	824		(11) chillums,
486	825
	826	+	SENATE FLOOR VERSION - HB1987 SFLR Page 17
	827	+	(Bold face denotes Committee Amendments) 1
	828	+	2
	829	+	3
	830	+	4
	831	+	5
	832	+	6
	833	+	7
	834	+	8
	835	+	9
	836	+	10
	837	+	11
	838	+	12
	839	+	13
	840	+	14
	841	+	15
	842	+	16
	843	+	17
	844	+	18
	845	+	19
	846	+	20
	847	+	21
	848	+	22
	849	+	23
	850	+	24
	851	+
487	852		(12) bongs, or
488		-
489	853		(13) ice pipes or chillers,
490	854		m. all hidden or novelty pipes, and
491		-
492	855		n. any pipe that has a tobacco bowl or chamber of less
493	856		than one-half (1/2) inch in diameter in which there is
494		-	any detectable residue of any controlled dangerous ~~ENR. H. B. NO. 1987 Page 12~~
	857	+	any detectable residue of any controlled dangerous
495	858		substance as defined in this section or any other
496	859		substances not legal for possession or use;
497		-
498	860		provided, however, the term "drug paraphernalia" shall not include
499	861		separation gins intended for use in preparing tea or spice, clamps
500	862		used for constructing electrical equipme nt, water pipes designed for
501	863		ornamentation in which no detectable amount of an illegal substance
502	864		is found or pipes designed and used solely for smoking tobacco,
503	865		traditional pipes of an American Indian tribal religious ceremony,
504	866		or antique pipes that are th irty (30) years of age or older, or drug
505	867		testing strips possessed by a person for purposes of determining the
506	868		presence of fentanyl or a fentanyl -related compound;
507		-
508	869		37. a. "Synthetic controlled substance" means a substance:
509		-
510	870		(1) the chemical structure of which is substantially
511	871		similar to the chemical structure of a controlled
512	872		dangerous substance in Schedule I or II,
513		-
514	873		(2) which has a stimulant, depressant, or
515	874		hallucinogenic effect on the central nervous
516	875		system that is substantially similar to or
	876	+
	877	+	SENATE FLOOR VERSION - HB1987 SFLR Page 18
	878	+	(Bold face denotes Committee Amendments) 1
	879	+	2
	880	+	3
	881	+	4
	882	+	5
	883	+	6
	884	+	7
	885	+	8
	886	+	9
	887	+	10
	888	+	11
	889	+	12
	890	+	13
	891	+	14
	892	+	15
	893	+	16
	894	+	17
	895	+	18
	896	+	19
	897	+	20
	898	+	21
	899	+	22
	900	+	23
	901	+	24
	902	+
517	903		greater than the stimulant, depressant or
518	904		hallucinogenic effect on the central nervous
519	905		system of a controlled dangerous substance in
520	906		Schedule I or II, or
521		-
522	907		(3) with respect to a particular pe rson, which such
523	908		person represents or intends to have a stimulant,
524	909		depressant, or hallucinogenic effect on the
525	910		central nervous system that is substantially
526	911		similar to or greater than the stimulant,
527	912		depressant, or hallucinogenic effect on the
528	913		central nervous system of a controlled dangerous
529	914		substance in Schedule I or II.
530		-
531	915		b. The designation of gamma butyrolactone or any other
532	916		chemical as a precursor, pursuant to Section 2-322 of
533	917		this title, does not preclude a findin g pursuant to
534	918		subparagraph a of this paragr aph that the chemical is
535	919		a synthetic controlled substance.
536		-
537	920		c. "Synthetic controlled substance" does not include:
538		-
539		-	(1) a controlled dangerous substance, ENR. H. B. NO. 1987 Page 13
540		-
	921	+	(1) a controlled dangerous substance,
541	922		(2) any substance for which there is an approved new
542	923		drug application,
543		-
544	924		(3) with respect to a particular p erson any
545	925		substance, if an exemption is in effect for
546	926		investigational use, for that person under the
	927	+
	928	+	SENATE FLOOR VERSION - HB1987 SFLR Page 19
	929	+	(Bold face denotes Committee Amendments) 1
	930	+	2
	931	+	3
	932	+	4
	933	+	5
	934	+	6
	935	+	7
	936	+	8
	937	+	9
	938	+	10
	939	+	11
	940	+	12
	941	+	13
	942	+	14
	943	+	15
	944	+	16
	945	+	17
	946	+	18
	947	+	19
	948	+	20
	949	+	21
	950	+	22
	951	+	23
	952	+	24
	953	+
547	954		provisions of Section 505 of the Federal Food,
548	955		Drug and Cosmetic Act, Title 21 of the United
549	956		States Code, Section 355, to the extent conduct
550	957		with respect to such substance is pursuant to
551	958		such exemption, or
552		-
553	959		(4) any substance to the extent not intended for
554	960		human consumption before such an exemption takes
555	961		effect with respect to that substance.
556		-
557	962		d. Prima facie evidence that a substance containing
558	963		salvia divinorum has been enhanced, concentrated or
559	964		chemically or physically altered shall give rise to a
560	965		rebuttable presumption that the substance is a
561	966		synthetic controlled substance;
562		-
563	967		38. "Tetrahydrocannabinols" means all substances that have been
564	968		chemically synthesized to emulate the tetrahydrocannabinols of
565	969		marijuana, specifically including any tetrahydrocannabinols derived
566	970		from industrial hemp;
567		-
568	971		39. "Isomer" means the optical isomer, except as used in
569	972		subsections C and F of Section 2-204 of this title and paragraph 4
570	973		of subsection A of Section 2-206 of this title. As used in
571	974		subsections C and F of Section 2-204 of this title, "isomer" means
572	975		the optical, positional or geometric isomer. As used in paragraph 4
573	976		of subsection A of Section 2-206 of this title, the term "isomer"
574	977		means the optical or geometric isomer;
575	978
	979	+	SENATE FLOOR VERSION - HB1987 SFLR Page 20
	980	+	(Bold face denotes Committee Amendments) 1
	981	+	2
	982	+	3
	983	+	4
	984	+	5
	985	+	6
	986	+	7
	987	+	8
	988	+	9
	989	+	10
	990	+	11
	991	+	12
	992	+	13
	993	+	14
	994	+	15
	995	+	16
	996	+	17
	997	+	18
	998	+	19
	999	+	20
	1000	+	21
	1001	+	22
	1002	+	23
	1003	+	24
	1004	+
576	1005		40. "Hazardous materials" means materials, whether solid,
577	1006		liquid or gas, which are toxic to human, animal, aquatic or plant
578	1007		life, and the disposal of which materials is controlled by state or
579	1008		federal guidelines;
580		-
581	1009		41. "Anhydrous ammonia" means any substance that exhibits
582	1010		cryogenic evaporative behavior and tests positive for ammonia;
583		-	ENR. H. B. NO. 1987 Page 14
584	1011		42. "Acute pain" means pain, whether resulting from disease,
585	1012		accidental or intentional trauma or other cause, that the
586	1013		practitioner reasonably expects to last only a short period of time.
587	1014		"Acute pain" does not include chronic pain, pain being treated as
588	1015		part of cancer care, hospice or other end-of-life care, or pain
589	1016		being treated as part of palliative care;
590		-
591	1017		43. "Chronic pain" means pain that persists beyond the usual
592	1018		course of an acute disease or healing of an injury. "Chronic pain"
593	1019		may or may not be associated with an acute or chronic pathologic
594	1020		process that causes continuous or intermittent pain over months or
595	1021		years;
596		-
597	1022		44. "Initial prescription" means a prescription issued to a
598	1023		patient who:
599		-
600	1024		a. has never previously been issued a prescription for
601	1025		the drug or its pharmaceutical equivalent in the past
602	1026		year, or
603		-
604	1027		b. requires a prescription for the drug or its
605	1028		pharmaceutical equivalent due to a surgical procedure
	1029	+
	1030	+	SENATE FLOOR VERSION - HB1987 SFLR Page 21
	1031	+	(Bold face denotes Committee Amendments) 1
	1032	+	2
	1033	+	3
	1034	+	4
	1035	+	5
	1036	+	6
	1037	+	7
	1038	+	8
	1039	+	9
	1040	+	10
	1041	+	11
	1042	+	12
	1043	+	13
	1044	+	14
	1045	+	15
	1046	+	16
	1047	+	17
	1048	+	18
	1049	+	19
	1050	+	20
	1051	+	21
	1052	+	22
	1053	+	23
	1054	+	24
	1055	+
606	1056		or new acute event and has previously had a
607	1057		prescription for the drug or its pharmaceutical
608	1058		equivalent within the past year.
609		-
610	1059		When determining whether a patient was previously issued a
611	1060		prescription for a drug or its pharmaceutical eq uivalent, the
612	1061		practitioner shall consult with the patient and review the medical
613	1062		record and prescription monitoring information of the patient;
614		-
615	1063		45. "Patient-provider agreement" means a written contract or
616	1064		agreement that is executed between a practitioner and a patient,
617	1065		prior to the commencement of treatment for chronic pain using an
618	1066		opioid drug as a means to:
619		-
620	1067		a. explain the possible risk of development of physical
621	1068		or psychological dependence in the patient and prevent
622	1069		the possible development of addiction,
623	1070		b. document the understanding of both the practitioner
624	1071		and the patient regarding the patient-provider
625	1072		agreement of the patient,
626	1073		c. establish the rights of the patient in association
627	1074		with treatment and the obligations of the patient in
628		-	relation to the resp onsible use, discontinuation of ~~ENR. H. B. NO. 1987 Page 15~~
	1075	+	relation to the resp onsible use, discontinuation of
629	1076		use, and storage of opioid drugs, including any
630	1077		restrictions on the refill of prescriptions or the
631	1078		acceptance of opioid prescriptions from practitioners,
	1079	+
	1080	+	SENATE FLOOR VERSION - HB1987 SFLR Page 22
	1081	+	(Bold face denotes Committee Amendments) 1
	1082	+	2
	1083	+	3
	1084	+	4
	1085	+	5
	1086	+	6
	1087	+	7
	1088	+	8
	1089	+	9
	1090	+	10
	1091	+	11
	1092	+	12
	1093	+	13
	1094	+	14
	1095	+	15
	1096	+	16
	1097	+	17
	1098	+	18
	1099	+	19
	1100	+	20
	1101	+	21
	1102	+	22
	1103	+	23
	1104	+	24
632	1105
633	1106		d. identify the specific medications and other modes of
634	1107		treatment, including physical therapy or exercise,
635	1108		relaxation or psychological counseling, that are
636	1109		included as a part of the patient-provider agreement,
637		-
638	1110		e. specify the measures the practitioner may employ to
639	1111		monitor the compliance of the patient including, but
640	1112		not limited to, random specimen screens and pill
641	1113		counts, and
642		-
643	1114		f. delineate the process for terminating the agreement,
644	1115		including the consequences if the practitioner has
645	1116		reason to believe that the patient is not complying
646	1117		with the terms of the agreement . Compliance with the
647	1118		"consent items" shall constitute a valid, informed
648	1119		consent for opioid therapy. The practitioner shall be
649	1120		held harmless from civil litigation for failure to
650	1121		treat pain if the event occurs because of nonadherence
651	1122		by the patient with any of the pro visions of the
652	1123		patient-provider agreement;
653		-
654	1124		46. "Serious illness" means a medical illness or physical
655	1125		injury or condition that substantially affects quality of life for
656	1126		more than a short period of time. "Serious illness" includes, but
657	1127		is not limited to, A lzheimer's disease or related dementias, lung
658	1128		disease, cancer, heart failure, renal failure, liver failure or
	1129	+
	1130	+	SENATE FLOOR VERSION - HB1987 SFLR Page 23
	1131	+	(Bold face denotes Committee Amendments) 1
	1132	+	2
	1133	+	3
	1134	+	4
	1135	+	5
	1136	+	6
	1137	+	7
	1138	+	8
	1139	+	9
	1140	+	10
	1141	+	11
	1142	+	12
	1143	+	13
	1144	+	14
	1145	+	15
	1146	+	16
	1147	+	17
	1148	+	18
	1149	+	19
	1150	+	20
	1151	+	21
	1152	+	22
	1153	+	23
	1154	+	24
	1155	+
659	1156		chronic, unremitting or intractable pain such as neuropathic pain;
660	1157		and
661		-
662	1158		47. "Surgical procedure" means a procedure that is performed
663	1159		for the purpose of structurally altering the human body by incision
664	1160		or destruction of tissues as part of the practice of medicine. This
665	1161		term includes the diagnostic or therapeutic treatment of conditions
666	1162		or disease processes by use of instruments such as lasers,
667	1163		ultrasound, ionizing, radiation, scalpels, probes or needles that
668	1164		cause localized alteration or transportation of live human tissue by
669	1165		cutting, burning, vaporizing, freezing, suturing, probing or
670	1166		manipulating by closed reduction for major dislocations or
671	1167		fractures, or otherwise altering by any mechanical, thermal, light-
672	1168		based, electromagnetic or chemical means.
673		-	ENR. H. B. NO. 1987 Page 16
674	1169		SECTION 2. This act shall become effective November 1, 2023.
675		-	ENR. H. B. NO. 1987 Page 17
676		-	Passed the House of Representatives the 23rd day of March, 2023.
677		-
678		-
679		-
680		-
681		-	Presiding Officer of the House
682		-	of Representatives
683		-
684		-
685		-
686		-	Passed the Senate the 25th day of April, 2023.
687		-
688		-
689		-
690		-
691		-	Presiding Officer of the Senate
692		-
693		-
694		-	OFFICE OF THE GOVERNOR
695		-	Received by the Office of the Governor this ____________________
696		-	day of ___________________, 20___ ____, at _______ o'clock _______ M.
697		-	By: _________________________________
698		-	Approved by the Governor of the State of Oklahoma this _____ ____
699		-	day of ___________________, 20_______, at _______ o'clock _______ M.
700		-
701		-
702		-	_________________________________
703		-	Governor of the State of Oklahoma
704		-
705		-	OFFICE OF THE SECRETARY OF STATE
706		-	Received by the Office of the Secretary of State this __________
707		-	day of ___________________, 20_______, at _______ o'clock _______ M.
708		-	By: _________________________________
	1170	+	COMMITTEE REPORT BY: COMMITTEE ON HEALTH AND HUMAN SERVICES
	1171	+	April 13, 2023 - DO PASS